Lifeward (LFWD) announced that it has closed on the company’s previously announced strategic partnership agreement with Oramed Pharmaceuticals (ORMP). The transaction has positioned Lifeward as a diversified biomedical innovation company with an expected clear path to profitability. Lifeward acquired Oramed’s clinical-stage Protein Oral Delivery technology, adding exposure to a large, long-term biotech market opportunity. Through the new partnership, Lifeward has access to up to $47M of capital from Oramed and certain investors, and on March 25, Lifeward accessed $10M of such capital.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on LFWD:
- Lifeward Faces Nasdaq Audit Committee Compliance Challenge
- Lifeward price target adjusted to $10 from $4.50 at H.C. Wainwright
- Lifeward reports Q4 adjusted EPS ($2.85) vs. ($4.54) last year
- Lifeward Shareholders Approve Oratech Deal and Governance Changes
- Lifeward receives shareholder approval to close on partnership with Oramed